Veuillez utiliser cette adresse pour citer ce document : http://dspace1.univ-tlemcen.dz/handle/112/2491
Affichage complet
Élément Dublin CoreValeurLangue
dc.contributor.authorGriffiths, G-
dc.contributor.authorLuger, T-
dc.contributor.authorBrault, Y-
dc.contributor.authorGermain, JM-
dc.contributor.authormallbris, L-
dc.date.accessioned2013-07-13T10:56:03Z-
dc.date.available2013-07-13T10:56:03Z-
dc.date.issued2013-
dc.identifier.urihttp://dspace.univ-tlemcen.dz/handle/112/2491-
dc.description.abstractA post hoc analysis of the randomised ; open -label , 54 - week multicentre CRYSTEL study showed pasients who achienved a clinical response ( physi cian global assessmen of psoriasis [PGA]<=2) on etanercept (ETN)50mg twice weekly (BIW) then paused treatement and subsequently relapsed (PGA)>2 were able to recapture the response after retreatement with ETN 25 mg BIW .in clinical practice , however , patient with (PGA <=1 (clear /almost clear ) are more likely to be candidates foren_US
dc.language.isoenen_US
dc.publisherjournal of the european academy of dermatology and venereologyen_US
dc.publisherUniversity of Tlemcenen_US
dc.titleRetreatement in patients achie ving response after relapse due to trea tment interruption : results from the crystel studyen_US
dc.typeArticleen_US
Collection(s) :Articles internationaux



Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.